Ossoli A, Wolska A, Remaley A T, et al. High-density lipoproteins: a promising tool against cancer[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2022, 1867(1):159068.
[2]
Zhao G J, Yin K, Fu Y C, et al. The interaction of ApoA-I and ABCA1 triggers signal transduction pathways to mediate efflux of cellular lipids[J]. Mol Med, 2012, 18(1):149-158.
[3]
Milasan A, Jean G, Dallaire F, et al. Apolipoprotein A-I modulates atherosclerosis through lymphatic vessel-dependent mechanisms in mice[J]. J Am Heart Assoc, 2017, 6(9).
[4]
Barter P J, Rye K A, Tardif J C, et al. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events(ILLUMINATE) trial[J]. Circulation, 2011, 124(5):555-562.
[5]
Schwartz G G, Leiter L A, Ballantyne C M, et al. Dalcetrapib reduces risk of new-onset diabetes in patients with coronary heart disease[J]. Diabetes Care, 2020, 43(5):1077-1084.
[6]
Feng X, Gao X, Yao Z, et al. Low apoA-I is associated with insulin resistance in patients with impaired glucose tolerance: a cross-sectional study[J]. Lipids Health Dis, 2017, 16(1):69.
[7]
Fritzen A M, Domingo-Espín J, Lundsgaard A M, et al. ApoA-1 improves glucose tolerance by increasing glucose uptake into heart and skeletal muscle independently of AMPKα(2)[J]. Mol Metab, 2020, 35:100949.
[8]
Tang S, Tabet F, Cochran B J, et al. Apolipoprotein A-I enhances insulin-dependent and insulin-independent glucose uptake by skeletal muscle[J]. Sci Rep, 2019, 9(1):1350.
[9]
McGrath K C, Li X, Twigg S M, et al. Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice[J]. PLoS One, 2020, 15(1):e0226931.
[10]
Edmunds S J, Liébana-García R, Nilsson O, et al. ApoAI-derived peptide increases glucose tolerance and prevents formation of atherosclerosis in mice[J]. Diabetologia, 2019, 62(7):1257-1267.
[11]
Coelho D R, Carneiro P H, Mendes-Monteiro L, et al. ApoA1 neutralizes proinflammatory effects of Dengue Virus NS1 protein and modulates viral immune evasion[J]. J Virol, 2021, 95(13):e0197420.
[12]
Caipang C M, Hynes N, Puangkaew J, et al. Intraperitoneal vaccination of Atlantic cod, Gadus morhua with heat-killed Listonella anguillarum enhances serum antibacterial activity and expression of immune response genes[J]. Fish Shellfish Immunol, 2008, 24(3):314-322.
Jiang R, Yang Z H, Luo D H, et al. Elevated apolipoprotein A-I levels are associated with favorable prognosis in metastatic nasopharyngeal carcinoma[J]. Med Oncol, 2014, 31(8):80.
[15]
Wu J, Zhang C, Zhang G, et al. Association between pretreatment serum apolipoprotein A1 and prognosis of solid tumors in chinese population: A systematic review and meta-analysis[J]. Cell Physiol Biochem, 2018, 51(2):575-588.
[16]
Shi H, Huang H, Pu J, et al. Decreased pretherapy serum apolipoprotein A-I is associated with extent of metastasis and poor prognosis of non-small-cell lung cancer[J]. Onco Targets Ther, 2018, 11:6995-7003.
[17]
Pedersen K M, Çolak Y, Bojesen S E, et al. Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116,728 individuals[J]. J Hematol Oncol, 2020, 13(1):129.
[18]
Martin L J, Melnichouk O, Huszti E, et al. Serum lipids, lipoproteins, and risk of breast cancer: a nested case-control study using multiple time points[J]. J Natl Cancer Inst, 2015, 107(5).
[19]
Zografos E, Anagnostopoulos A K, Papadopoulou A, et al. Serum proteomic signatures of male breast cancer[J]. Cancer Genomics Proteomics, 2019, 16(2):129-137.
[20]
His M, Zelek L, Deschasaux M, et al. Prospective associations between serum biomarkers of lipid metabolism and overall, breast and prostate cancer risk[J]. Eur J Epidemiol, 2014, 29(2):119-132.
[21]
Nowak C, Ärnlöv J. A Mendelian randomization study of the effects of blood lipids on breast cancer risk[J]. Nat Commun, 2018, 9(1):3957.
[22]
Beeghly-Fadiel A, Khankari N K, Delahanty R J, et al. A mendelian randomization analysis of circulating lipid traits and breast cancer risk[J]. Int J Epidemiol, 2020, 49(4):1117-1131.
[23]
Bull C J, Bonilla C, Holly J M, et al. Blood lipids and prostate cancer: a mendelian randomization analysis[J]. Cancer Med, 2016, 5(6):1125-1136.
[24]
Carreras-Torres R, Johansson M, Gaborieau V, et al. The role of obesity, type 2 diabetes, and metabolic factors in pancreatic cancer: a mendelian randomization study[J]. J Natl Cancer Inst, 2017, 109(9).
[25]
Lu Y, Gentiluomo M, Lorenzo-Bermejo J, et al. Mendelian randomisation study of the effects of known and putative risk factors on pancreatic cancer[J]. J Med Genet, 2020, 57(12):820-828.
[26]
Traughber C A, Opoku E, Brubaker G, et al. Uptake of high-density lipoprotein by scavenger receptor class B type 1 is associated with prostate cancer proliferation and tumor progression in mice[J]. J Biol Chem, 2020, 295(24):8252-8261.
[27]
Ma X L, Gao X H, Gong Z J, et al. Apolipoprotein A1: a novel serum biomarker for predicting the prognosis of hepatocellular carcinoma after curative resection[J]. Oncotarget, 2016, 7(43):70654-70668.
[28]
McKenzie J A, Grossman D. Role of the apoptotic and mitotic regulator survivin in melanoma[J]. Anticancer Res, 2012, 32(2):397-404.
[29]
Zhang T, Wang Q, Wang Y, et al. AIBP and APOA-I synergistically inhibit intestinal tumor growth and metastasis by promoting cholesterol efflux[J]. J Transl Med, 2019, 17(1):161.
[30]
Zamanian-Daryoush M, Lindner D J, Buffa J, et al. Apolipoprotein A-I anti-tumor activity targets cancer cell metabolism[J]. Oncotarget, 2020, 11(19):1777-1796.
[31]
Anderson N M, Simon M C. The tumor microenvironment [J]. Curr Biol, 2020, 30(16):R921-r925.
[32]
Kozak K R, Amneus M W, Pusey S M, et al. Identification of biomarkers for ovarian cancer using strong anion-exchange protein chips: potential use in diagnosis and prognosis[J]. Proc Natl Acad Sci U S A, 2003, 100(21):12343-12348.
[33]
Shi F, Wu H, Qu K, et al. Identification of serum proteins AHSG, FGA and APOA-I as diagnostic biomarkers for gastric cancer[J]. Clin Proteomics, 2018, 15:18.
[34]
Chen C, Yi W, Zeng Z F, et al. Serum apolipoprotein B to apolipoprotein A-I ratio is an independent predictor of liver metastasis from locally advanced rectal cancer in patients receiving neoadjuvant chemoradiotherapy plus surgery[J]. BMC Cancer, 2022, 22(1):7.
[35]
Liu M M, Chen Z H, Zhao L Y, et al. Prognostic value of serum apolipoprotein B to apolipoprotein A-I ratio in hepatocellular carcinoma patients treated with transcatheter arterial chemoembolization: a propensity score-matched analysis[J]. Oncol Res Treat, 2021, 44(9):450-468.
[36]
Chen J, Chen Y J, Jiang N, et al. Neutrophil-to-Apolipoprotein A1 ratio predicted overall survival in hepatocellular carcinoma receiving transarterial chemoembolization[J]. Oncologist, 2021, 26(8):e1434-e1444.
[37]
Chattopadhyay A, Yang X, Mukherjee P, et al. Treating the intestine with oral ApoA-I mimetic Tg6F reduces tumor burden in mouse models of metastatic lung cancer[J]. Sci Rep, 2018, 8(1):9032.
[38]
Marinho A T, Lu H, Pereira S A, et al. Anti-tumorigenic and platinum-sensitizing effects of apolipoprotein A1 and apolipoprotein A1 mimetic peptides in ovarian cancer[J]. Front Pharmacol, 2018, 9:1524.
[39]
Henrich S E, Hong B J, Rink J S, et al. Supramolecular assembly of high-density lipoprotein mimetic nanoparticles using lipid-conjugated core scaffolds[J]. J Am Chem Soc, 2019, 141(25):9753-9757.
[40]
Kuai R, Ochyl L J, Bahjat K S, et al. Designer vaccine nanodiscs for personalized cancer immunotherapy[J]. Nat Mater, 2017, 16(4):489-496.
[41]
Shahzad M M, Mangala L S, Han H D, et al. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles[J]. Neoplasia, 2011, 13(4):309-319.
[42]
Yuan Y, Wen J, Tang J, et al. Synthetic high-density lipoproteins for delivery of 10-hydroxycamptothecin[J]. Int J Nanomedicine, 2016, 11:6229-6238.
[43]
Subramanian C, Kuai R, Zhu Q, et al. Synthetic high-density lipoprotein nanoparticles: A novel therapeutic strategy for adrenocortical carcinomas[J]. Surgery, 2016, 159(1):284-294.
[44]
Gradishar W J, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer[J]. J Clin Oncol, 2005, 23(31):7794-7803.
[45]
Rui M, Xin Y, Li R, et al. Targeted Biomimetic nanoparticles for synergistic combination chemotherapy of paclitaxel and doxorubicin[J]. Mol Pharm, 2017, 14(1):107-123.
[46]
Dong J, Li W, Dong A, et al. Gene therapy for unresectable hepatocellular carcinoma using recombinant human adenovirus type 5 [J]. Med Oncol, 2014, 31(8):95.
[47]
Ding Y, Wang Y, Zhou J, et al. Direct cytosolic siRNA delivery by reconstituted high density lipoprotein for target-specific therapy of tumor angiogenesis[J]. Biomaterials, 2014, 35(25):7214-7227.
[48]
McMahon K M, Plebanek M P, Thaxton CS. Properties of native high-density lipoproteins inspire synthesis of actively targeted In vivo siRNA delivery vehicles[J]. Adv Funct Mater, 2016, 26(43):7824-7835.
[49]
Kadiyala P, Li D, Nuñez F M, et al. High-Density lipoprotein-mimicking nanodiscs for chemo-immunotherapy against glioblastoma multiforme[J]. ACS Nano, 2019, 13(2):1365-1384.
[50]
Tripathy S, Vinokour E, McMahon K M, et al. High density lipoprotein nanoparticles deliver RNAi to endothelial cells to inhibit angiogenesis[J]. Part Syst Charact, 2014, 31(11):1141-1150.
[51]
Wang Y, Wang C, Ding Y, et al. Biomimetic HDL nanoparticle mediated tumor targeted delivery of indocyanine green for enhanced photodynamic therapy[J]. Colloids Surf B Biointerfaces, 2016, 148:533-540.
[52]
Seo J, Yun C O, Kwon O J, et al. A proteoliposome containing apolipoprotein A-I mutant(V156K) enhances rapid tumor regression activity of human origin oncolytic adenovirus in tumor-bearing zebrafish and mice[J]. Mol Cells, 2012, 34(2):143-148.
2025, Vol. 36 
